Year: 2024
Type: article
Abstract: In this issue of Blood Advances, Ledergor et al 1 describe the results of an elegant study using singlecell transcriptomics to study changes in immune cells in patients with multiple myeloma (MM) receiving chimeric antigen receptor (CAR) T cells (CAR-Ts) targeting B-cell maturation antigen (BCMA).Study population consisted of 15 patients with relapsed MM enrolled in clinical trials of 4 different CAR-Ts.In spite of these differences, patients with durable responses had greater persistence of infused CAR-Ts, whereas those with short-lived responses had increased frequencies of exhausted cytotoxic CD4 + CAR-Ts (see figure).These findings illustrate the power of single-cell approaches and provide insights into how the biology of CAR-Ts may affect outcomes in MM.
Source: Blood Advances
Author: Madhav V. Dhodapkar
Institution: Emory University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W4400451886